News

ReAlta Doses First Patient in Phase 2 STAR Study of RLS-0071 for HIE in Newborns

ReAlta Life Sciences (“ReAlta”), Inc., a clinical mid-stage biotech company dedicated to addressing life-threatening rare diseases by harnessing the power of the immune system,  announced dosing of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071 for the treatment of hypoxic ischemic encephalopathy (HIE) in newborns. RLS-0071, an investigational new drug, is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development for the treatment of HIE, acute GvHD and acute COPD.

“The novel, dual-targeting mechanisms of action of RLS-0071, rapidly inhibiting both the complement cascade at C1 and cellular inflammation through the inhibition of myeloperoxidase (MPO) activity and NETosis, hold great promise to address the fundamental drivers of the HIE disease process,” said ReAlta Chief Medical Officer Kenji Cunnion, MD, MPH. “This study is an important step forward in developing an effective therapy to reduce the burden of this devastating neurological disease on patients and their families.”

Ulrich Thienel, MD, Ph.D., ReAlta Chief Executive Officer said, “This is a special day for ReAlta and the patients we hope to serve, as we announce the dosing of the first patient in the first human efficacy trial in our company’s history. HIE is a disease with incredible unmet need, profoundly affecting the lives of thousands of children born each year in the U.S. and many more across the world. I am proud of the work of our team and thankful for the support from clinicians and colleagues in the patient community who have enabled this important milestone.”

The Phase 2 clinical trial is a two-stage, randomized, double-blind, placebo controlled, multiple-ascending dose study to evaluate the Safety, Tolerability, pharmAcokinetics, and preliminary efficacy of RLS-0071 in newboRns with moderate or severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia with long-term follow up (STAR). In Stage 1, approximately 40 participants will receive either ascending doses of RLS-0071 or placebo in addition to standard of care treatment, including hypothermia for 72 hours. After completion of Stage 1, participants will transition to Stage 2 of the study for long-term observation out to 24 months of age. The primary endpoint of the study is safety. Key secondary endpoints include measures of mortality, seizure burden, and neurocognitive development. For more information about the Phase 2 STAR study, visit https://www.clinicaltrials.gov (NCT05778188).

HIE, also known as birth asphyxia, is a rare disease that affects newborns suffering an abrupt, unexpected loss of oxygenation due to placental rupture, umbilical cord problems, or other factors. The initial loss of oxygen and the dysregulated inflammatory process that follows causes damage to the brain and other organs. This acute disease often results in death or moderate-to-severe cognitive and physical disability, with life-long impacts on both the newborn and the newborn’s family.

Recent News

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep

07/14/2025

Nanochon Announces Health Canada Approval for First in Human Investigation

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with